NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicans and payors
New Clinical Guidelines For Prostate Cancer To Be Released
FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer Pursuing New Paradigms in Prostate Cancer Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate...
Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4–23 (2017). Article CAS Pub...
M. et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat. Rev. Urol. 13, 151–167 (2016). Article CAS PubMed Google Scholar Barrett, T. & Haider, M. A. The emerging role of MRI in prostate cancer active surveillance and ongoing challenges. AJR...
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Horwich, A, Parker, C, Reijke, T, Kataja, V (2013) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann ......
T-DXd has been included in the NCCN guidelines as a class I-preferred second-line treatment for recurrent unresectable (local or regional) or stage IV HER2-positive breast cancer [63]. The cytotoxic bystander effect of T-DXd causes the release of the payload to be membrane-permeable, inducing...
New Guidelines Stress Uniformity of Clinical Trials for Relapsed Prostate CancerAdministrator
Karen S Raraigh, Margaret Rosenfeld, Quan Sun, Jia Wen, Yun Li, Harriet Corvol, Lisa J Strug, Michael J Bamshad, Scott M Blackman, Garry R Cutting, Ronald L Gibson, Wanda K O'Neal, Fred A Wright, Michael R Knowles Guidelines for genetic ancestry inference created through roundtable dis...
Newer targeted options entered the NCCN Guidelines for metastatic urothelial cancer more than 1 year ago, “but they may still be new in the minds of many,” she said. They include the following agents: Erdafitinib, the first biomarker-directed therapy to be approved in this setting ...